Gen-Probe buy hits Hologic's Q4 profits but set to boost future growth; analysts predict bottom-line increase for Medtronic
This article was originally published in Clinica
Executive Summary
Women's health specialist Hologic swung to a net loss during its fourth fiscal quarter as it was hit by charges relating to its $3.7bn acquisition of molecular diagnostics firm Gen-Probe, agreed in May (www.clinica.co.uk, 1 May 2012). The deal closed in August.